Sorry, you need to enable JavaScript to visit this website.

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign-up to receive all GMG announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts
Title
Grant Type
Focus Area
Country
Application Due Date
Research in Ulcerative Colitis (UC) 2024
Release Date:
Review Process: Expert Review Panel
Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Research Oncology USA
BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Translation: Japanese (link)
Education Oncology Japan
Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophilia
Release Date:
Review Process: Pfizer Internal
Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom
Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)
Release Date:
Review Process: Pfizer Internal
Education Rare Disease All
Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)
Release Date:
Partner: Sumitomo Pharma
Review Process: Pfizer Internal
Education Oncology USA
Title
Grant Type
Focus Area
Country
Application Due Date
Education of Healthcare Professionals to Provide Appropriate Medical Care for Patients with Atopic Dermatitis
Release Date:
Review Process: Pfizer Internal
Education Inflammation & Immunology Japan
Enzalutamide in the Treatment of Prostate Cancer
Release Date:
Partner: National Comprehensive Cancer Network, Astellas
Review Process: Expert Review Panel
Research Oncology USA
Addressing Primary Immunodeficiencies within Minority/Underserved Populations
Release Date:
Review Process: Pfizer Internal
Education Hospital USA
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research – U.S.
Release Date:
Review Process: Pfizer Internal
Research Rare Disease USA
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator Competitive Grant Program
Release Date:
Review Process: Pfizer Internal
Quality Improvement Rare Disease USA
Patient and Caregiver Awareness of Drug Resistant Infections (United States and Europe)
Release Date:
Review Process: Pfizer Internal
Education Hospital All
Establishment of Hospital-Clinic Collaboration Model for Undiagnosed Rheumatic Diseases
Release Date:
Partner: The Japan College of Rheumatology
Review Process: Expert Review Panel
Quality Improvement Inflammation & Immunology Japan
A Quality Improvement Grant Request for Proposals Addressing Social Health Needs in Chronic and Preventative Disease
Release Date:
Partner: IHI
Review Process: Expert Review Panel
Quality Improvement Internal Medicine USA
Establishment of Support System for Healthy Life Extension of Patients with CV disease
Release Date:
Review Process: Expert Review Panel
Quality Improvement Internal Medicine Japan
Racial and Ethnic Disparities in the Menopause Experience
Release Date:
Review Process: Pfizer Internal
Education Internal Medicine USA
Immunotherapy in Urothelial Carcinoma
Release Date:
Partner: Merck KGaA Darmstadt, Germany and EMD Serono
Review Process: Pfizer Internal
Education Oncology All
Managment of Metabolic Risks that Drive Liver Diseases and Increase Cardiovascular Risk in NASH
Release Date:
Review Process: Pfizer Internal
Education Internal Medicine All